NOTE B  ACQUISITIONS AND STRATEGIC INVESTMENTS 2017 Acquisitions Symetis SA On May 16, 2017 we completed the acquisition of Symetis SA (Symetis) for approximately $430 million in cash. Symetis is a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices. Upon completion of the acquisition, we began selling the ACURATE TA, ACURATE neo ACURATE TF Valve Systems in Europe and in other geographies outside of the United States. We are in the process of integrating Symetis into our Interventional Cardiology business and expect the integration to be substantially complete by the end of 2018. Purchase Price Allocation We accounted for the acquisition of Symetis as a business combination and, in accordance with FASB ASC Topic 805 , Business Combinations , we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The components of the aggregate preliminary purchase price are as follows (in millions): Net cash paid for acquisition $ 392 The following summarizes the preliminary purchase price allocation for the Symetis acquisition as of June 30, 2017 (in millions): Goodwill $ 185 Amortizable intangible assets 278 Other assets acquired 25 Liabilities assumed (96 ) $ 392 We allocated a portion of the purchase price to specific intangible asset categories as follows: Amount Assigned (in millions) Amortization Period (in years) Range of Risk- Adjusted Discount Rates used in Purchase Price Allocation Amortizable intangible assets: Technology-related $ 268 13 23.5% Other intangible assets 10 2-13 23.5% $ 278 2016 Acquisitions We did not close any significant acquisitions during the first half of 2016. Contingent Consideration Certain of our acquisitions involve contingent consideration arrangements. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels, achieving product development